Except for hematological tumors, CD38-targeting therapy, as one of the major discussed immune cell-depleting based strategies, has also been investigated and practiced in clinical trials of a wide range of diseases including SLE (24, 37), ITP (38) and IgA nephropathy (IgAN) (39, 40). This evidence concerns the gene CD38 and IgA glomerulonephritis.